Novo Nordisk CEO to Testify in U.S. Senate Hearing on High Cost of Ozempic, Wegovy
(Reuters) – The Senate Committee on Health, Education, Labor, and Pensions announced on Friday that Novo Nordisk CEO Lars Jorgensen has agreed to testify voluntarily in an upcoming hearing focused on U.S. prices for weight loss drugs Ozempic and Wegovy.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
